Sage Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Sage Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-2.9%

Buyback Yield

Total Shareholder Yield	-2.9%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

CNS Drug Development: Same As It Ever Was

Nov 19

Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left

Oct 07

Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Aug 30

Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)

Jul 25

Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Jul 13

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

May 30

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

May 21

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Feb 22

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Feb 15

Sizing Up Sage Therapeutics

Jan 22

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Aug 09

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Feb 22

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Nov 12

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Oct 14

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Aug 02

What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

Aug 05

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SAGE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SAGE's dividend payments have been increasing.

Dividend Yield vs Market

Sage Therapeutics Dividend Yield vs Market

How does SAGE dividend yield compare to the market?
Segment	Dividend Yield
Company (SAGE)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.5%
Analyst forecast (SAGE) (up to 3 years)	0%

Notable Dividend: Unable to evaluate SAGE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SAGE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate SAGE's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SAGE has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 11:35
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sage Therapeutics, Inc. is covered by 39 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Joel Beatty	Baird
Esther Lannie Hong	Berenberg
null null	BMO Capital Markets Equity Research

Sage Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

CNS Drug Development: Same As It Ever Was

Sage Therapeutics, Inc.'s CFO Kimi Iguchi to Depart Amid Leadership Changes

Sage Therapeutics, Inc. Announces Executive Changes

Sage Therapeutics, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Sage Therapeutics Announces Topline Results from the Phase 2 Lightwave Study of Dalzanemdor (Sage-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’S Disease

Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Holzer & Holzer, LLC Announces a Class Action Lawsuit Has Been Filed Against Sage Therapeutics, Inc

Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 2500 Growth Index

Sage Therapeutics, Inc. Announces Topline Results from the Phase 2 SURVEYOR Study

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 32%, EPS downgraded

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 13% to US$24.39

Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Consensus revenue estimates fall by 50%

Consensus revenue estimates fall by 50%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Sage Therapeutics, Inc. to Report Q4, 2023 Results on Feb 14, 2024

Sizing Up Sage Therapeutics

Price target decreased by 13% to US$21.94

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Insufficient new directors

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%

Consensus revenue estimates fall by 57%

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 21% to US$48.06

Sage Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insider recently bought US$51k worth of stock

Consensus revenue estimates increase by 14%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

President recently bought US$500k worth of stock

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Sage Therapeutics Appoints Laura M. Gault as Chief Medical Officer

Sage Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 Skylark Study of Zuranolone in Postpartum Depression At the European College of Neuropsychopharmacology (Ecnp) Congress

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Sage Therapeutics, Inc. Enters into Settlement Agreement

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Dynamic Index

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics, Inc. Provides Zuranolone New Drug Application Update

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Consensus revenue estimates fall by 62%

Insider recently bought US$252k worth of stock

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)

Sage Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 Luminary Study of Sage-718 in Patients with Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease

Sage Therapeutics: Well-Funded But Uninspiring Data